Latest Developments in IP Strategies for Pharmaceuticals
Summer 2022
International Pharmaceutical Industry
By Sara A. Leiman, Ph.D.; Jordan M. Gringauz; Amanda K. Murphy, Ph.D.; Stacy Lewis*
The strategies used to create and maintain strong pharmaceutical patent portfolios must evolve with developments in the pharmaceutical space. These developments include not just scientific advancements but also requirements and practices of regulatory bodies, such as the United States Food and Drug Administration (FDA). This article addresses innovative prosecution strategies and useful considerations that may facilitate better agreement between pharmaceutical patent practice and FDA policy.
Read "Latest Developments in IP Strategies for Pharmaceuticals"
Related Practices
Related Industries
Related Offices
Related Professionals
- Sara A. Leiman, Ph.D.
- Associate
- Boston, MA
- +1 617 646 1651
- Jordan M. Gringauz
- Associate
- Washington, DC
- +1 202 408 4143
*Stacy Lewis is a Law Clerk at Finnegan.
Originally printed in International Pharmaceutical Industry in the Summer 2022 issue. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
